Mumbai: Indian company Godavari Biorefineries Limited has achieved a major milestone in cancer research. The US patent for its application, titled 'Compounds for the Inhibition of Unregulated Cell Growth,' has been officially approved. These compounds target cancer stem cells, which are responsible for the growth, spread, and recurrence of cancers, showing potential for treating breast and prostate cancer.
Stock Market Reaction
Following the announcement, the company’s shares surged sharply. The stock opened at Rs 237.50 on December 5, 2025, compared to the previous close of Rs 238.86, and within 30 minutes jumped 18 percent to over Rs 280. The trading volume also spiked, with 8 lakh shares traded in minutes, compared to the usual one lakh shares. The company’s market capitalization is Rs 1,400 crore.
Sensex & Nifty Storm Back After RBI Cuts Interest Rates By 25 Basis Points In A Bid To Bolster Economic GrowthAbout Godavari Biorefineries
Godavari Biorefineries is an integrated biorefinery company and part of the Somaiya Group. Primarily, it produces ethanol, bio-based chemicals, sugar, and power from sugarcane. The company is also engaged in medical research, focusing on innovative therapies for serious diseases.
Reliance Halts Russian Crude Processing At Jamnagar SEZ Refinery, Moves Early To Comply With Tightening EU-US Sanctions On Russian Oil ProductsHow the Patent Works
The US patent grants Godavari Biorefineries exclusive rights to use, manufacture, and sell these compounds in the US. No other company can commercially exploit the technology without permission. These compounds could form the basis for future cancer treatments with fewer side effects and greater effectiveness, potentially transforming cancer therapy models globally.
The Scientists Behind the Discovery
The research was led by an Indian team from Maharashtra: Sandeep Gawade, Maithili Athawale, Sangita Srivastava, and Prashant Khadkar. They have been working for years on compounds that can inhibit uncontrolled cell growth and target cancer stem cells directly.
HCC Approves ₹1,000 Crore Rights Issue, Shares Fall Over 22% Amid Market Reaction, Full Details InsideBenefits and Implications
This patent gives the company a strong foothold in the US market, opportunities for partnerships with global pharma companies, and recognition in cancer therapy innovation. Future commercial drugs based on these compounds could generate millions of dollars, while also offering affordable, safer, and more effective treatment options for patients in India and worldwide.
-
The Rupee Continues to Weaken! A Major Burden on the Pockets of Indian Students Studying Abroad
-
UP Board Exam 2026: Model papers for 10th and 12th uploaded. How has the paper pattern changed?
-
'No Engagement Ring, Heavy Voice': Smriti Mandhana’s First Post Amid Wedding Row Sparks Fans' Concerns
-
Garlic Benefits: Garlic is a ‘treasure of health’ in winter, Acharya Balkrishna reveals amazing benefits
-
Winter Superfood: Bathua can revive kidney and liver health, says Acharya Balkrishna
